$MYNDF News
Last published 4y ago
- 4y agoMYNDFMYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical TrialPR NewswireClinical validation of MYND Diagnostics' proprietary biomarkers in evaluating the efficacy of psilocybin-assisted psychotherapy in treatment-resistant depression VANCOUVER, BC, Feb. 8, 2022 /PRNewswire/ - MYND Diagnostics Inc., a wholly-owned subsidi
- 4y agoMYNDFMYND Life Sciences Announces Collaborative Research Agreement with the University of British ColumbiaPR NewswireMYND's Second CRA focuses on Novel Therapies for Neurological Diseases of the Brain VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE:MYND) (OTC:MYNDF) a biopharmaceutical research and development c
- 4y agoMYNDFMYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer's Disease and other DementiasPR NewswireAcquisition will strengthen MYND's psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the treatment of dementia, including Alzheimer's disease. VANCOUVER, BC, Dec. 17, 2021 /PRNewswire/ - Further to news release
- 4y agoMYNDFMYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent ApplicationPR NewswireVANCOUVER, BC, Dec. 15, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE:MYND) (OTC:MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following
- 4y agoMYNDFMYND Life Sciences announces funding for Psilocybin research on NeuroinflammationPR NewswireR&D project on psilocybin's benefits in treating diseases of the brain VANCOUVER, BC, Nov. 30, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE:MYND) (OTC:MYNDF) is pleased and extremely grateful to acknowledge the financ
- 4y agoMYNDFMYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker TestPR NewswireMYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics VANCOUVER, BC, Nov. 18, 2021 /PRNewswire/ - MYND LIFE SCIENCES INC. ("MYND" or the "Company") (CSE:MYN
- 4y agoMYNDFMYND Diagnostics Commences Clinical Research on Alzheimer's DiseasePR NewswireThe Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer's Disease diagnostics VANCOUVER, BC, Nov. 16, 2021 /PRNewswire/ - MYND LIFE SCIENCES INC. ("MYND" or the "Company") (CSE
- 5y agoCSE:CALMCSE:MYNDMYNDFRVLWFRevitalist Executes LOI to Enter into a Clinical Research Collaboration with MYNDBusiness WireREVITALIST LIFESTYLE AND WELLNESS LTD. ("Revitalist" or the "Company") (CSE:CALM) (OTC:RVLWF) (FSE: 4DO) is pleased to announce it has executed a binding letter of intent ("LOI") with MYND DIAGNOSTICS INC., ("MYND Diagnostics"), a wholly owned subsidiar
- 5y agoMYNDFRVLWFMYND Executes LOI to Enter into a Clinical Research Collaboration with RevitalistPR NewswireFocused on generating data through proprietary biomarkers and diagnostic testing of inflammation VANCOUVER, BC, Nov. 9, 2021 /PRNewswire/ - MYND LIFE SCIENCES INC. ("MYND" or the "Company") (CSE:MYND) (OTC:MYNDF) is pleased to announce its wholly
- 5y agoMYNDFMYND Life Sciences Announces Appointment of New DirectorPR NewswireVANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE:MYND) (OTC:MYNDF) announces the following changes to its Board of Directors.
- 5y agoMYNDFMYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer's Disease and other DementiasPR NewswireAcquisition will strengthen MYND's psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the treatment of dementia, including Alzheimer's disease. VANCOUVER, BC, Oct. 27, 2021 /PRNewswire/ - MYND Life Sciences Inc.
- 5y agoAWKNFBETRFBMBIFCYBN+16KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand ViewingPR NewswireNEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.
- 5y agoMYNDFMYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical TrialPR NewswireEvaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression VANCOUVER, BC, Oct. 13, 2021 /PRNewswire/ - MYND Diagnostics Inc., a wholly-owned subsidiary of MYND Life Sciences (CSE:MYND) (OTC:MYNDF) is pleased t
- 5y agoMYNDFMYND Life Sciences Inc. to Present at Psychedelics Virtual Investor Conference on October 13PR NewswireVANCOUVER, BC, Oct. 11, 2021 /PRNewswire/ -- MYND Life Sciences Inc. (CSE:MYND)(OTC:MYNDF), based in Vancouver BC, focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, today announced that MYND Life Sciences CEO, Dr
- 5y agoAWKNFBETRFBMBIFCYBN+13KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14thPR NewswireNEW YORK, Oct. 11, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional inves
- 5y agoMYNDFMYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary - MYND Diagnostics Ltd.PR NewswireMYND Diagnostics was formed to commercialize proprietary biomarker diagnostic tests for patients suffering from MDD, TRD and other psychiatric disorders. VANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ - MYND Life Sciences Inc. (CSE:MYND) (OTC:MYNDF) ("M
- 5y agoMYNDFMYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit OfferingPR NewswireVANCOUVER, BC, Sept. 9, 2021 /PRNewswire/ - MYND Life Sciences Inc. (CSE:MYND) (OTC:MYNDF) ("MYND" or the "Company") is pleased to announce, further to its news release of August 26, 2021, the closing of its non-brokered private placement offering (the
- 5y agoMYNDFMYND Life Sciences Announces $3 Million Convertible Debenture Unit OfferingPR NewswireVANCOUVER, BC, Aug. 26, 2021 /PRNewswire/ - MYND Life Sciences Inc. (CSE:MYND) (OTC:MYNDF) ("MYND" or the "Company"), is pleased to announce that it has entered into a binding term sheet in respect of a non-brokered private placement offering (the "O
- 5y agoMYNDFMYND Life Sciences Announces DTC EligibilityPR NewswireVANCOUVER, BC, Aug. 11, 2021 /PRNewswire/ - MYND Life Sciences Inc. (CSE:MYND) (OTC:MYNDF) ("MYND") is a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals and vaccines is p